FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR⁺) Breast Cancer.

ABSTRACT:

Purpose

While FGFR1 amplification has been described in breast cancer, the optimal treatment approach for FGFR1-amplified (FGFR1⁺) metastatic breast cancer (MBC) remains undefined.Experimental Design: We evaluated clinical response to endocrine and targeted therapies in a cohort of patients with hormone receptor-positive (HR⁺)/HER2^- MBC and validated the functional role of FGFR1-amplification in mediating response/resistance to hormone therapy in vitro.

Results

In the clinical cohort (N = 110), we identified that patients with FGFR1⁺ tumors were more likely to have progesterone receptor (PR)-negative disease (47% vs. 20%; P = 0.005), coexisting TP53 mutations (41% vs. 21%;

SUBMITTER: Drago JZ 

PROVIDER: S-EPMC6825550 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature